Mediterranean spotted fever is an acute infectious disease caused by Rickettsia conorii. During the last few years there has been a resurgence of this disease in Mediterranean countries.' Likewise, acquired sporadic cases have recently been reported in northern Europe2 3 and the United States. 4 Treatment with tetracyclines or chloramphenicol is effective, but tetracyclines can cause undesirable side effects, especially in children under the age of 8 years, and with chloramphenicol there is a risk of bone marrow toxicity.
Some cell culture studies have shown that erythromycin is an effective in vitro agent against various species of rickettsieae.5 6 We undertook a randomised clinical trial comparing tetracycline hydrochloride with erythromycin stearate to see if erythromycin could constitute a useful and less toxic therapeutic alternative in children with Mediterranean spotted fever.
Patients and methods
We included in the study all children diagnosed as having Mediterranean spotted fever and admitted during 1983 and 1984 to the Hospital de Sant Llatzer, Terrassa, and Clinica Infantil del Nen Jesus, Sabadell (Spain). Eight patients, who in the week preceding the study had received antibiotics, were not included in the trial; neither were those with a history of allergy to tetracyclines and erythromycin.
The diagnostic criteria of Mediterranean spotted fever were as follows: presence of typical clinical manifestations plus tache noire and/or a positive serologic result by means of indirect immunofluorescence against R. conorii (a fourfold increase in the titre of acute serum over convalescent serum or a titre over 1:40 in those few cases in whom only one test was possible).
Eighty one children fulfilled the conditions for inclusion in the study; 12 who did not were excluded. Patients were treated at random with either erythromycin stearate or tetracycline hydrochloride according to a set of computer generated aleatory numbers. Over a period of 10 days patients received daily doses of either erythromycin 50 mg/kg (12-5 mg/kg four times a day) or tetracycline 40 mg/kg (10 mg/kg four times a day). Temperature was taken at least every six hours by nursing personnel not related to the study, and symptoms were evaluated daily until disappearance.
On admission the following laboratory studies were carried out: haemogram, erythrocyte sedimentation rate, urea, creatinine, total bilirubin, and electrolyte concentrations, serum glutamic pyruvic transanimase, serum glutamic oxaloacetic transanimase, alkaline phosphatase, creatine kinase, and lactate dehydrogenase activities, prothrombin time, total protein and protein electrophoresis, urinalysis, Weil-Felix reaction, indirect immunofluorescence against R. conorii, and blood cultures. Electrocardiograms and chest x ray films were also obtained. At the end of three weeks a clinical revision and new serological, haematological, and biochemical determinations were made. Apyrexia was defined as a temperature of less than 37°C taken in the armpit. Student's t test was used for statistical analysis.
Results
Of the 81 patients studied, 50 were boys and 31 girls. Ages ranged between 1 and 13 years. Thirty four patients received tetracycline hydrochloride and 46 erythromycin. One patient began treatment with erythromycin but was later switched to tetracycline. This 7 year old boy presented with fever, headache, and myalgias of 24 hours' duration. On physical examination a tache noire was noticed on the scalp accompanied by enlarged lymph nodes and maculopapular rash affecting the palms of the hands and the soles of the feet. There was no improvement of clinical manifestations, with persistence of high fever (39-40'C), headache, myalgias, and prostration on the eighth day of treatment with erythromycin. After two days of treatment with tetracycline fever subsided and clinical symptoms markedly improved. As the patient had not completed the prescribed 10 day course of antibiotic regimen this case was not evaluated in the results, and we think that this must be considered as an example of erythromycin proving ineffective.
Mean (SD) ages of the patients were similar in both groups (6-9 (2-2) years in the group treated with tetracycline v 5-9 (2.6) years in the group treated with erythromycin). Maximal temperatures recorded on admission were also similar (39-6 (0.6)°C v 39.5 (0-7)°C, respectively). The interval This study shows that tetracycline hydrochloride is superior to erythromycin stearate in the treatment of Mediterranean spotted fever. Symptoms and fever disappeared significantly more rapidly in the group treated with tetracycline. Although the difference in the total duration of fever between the two groups was not significant, this is probably due to the fact that treatment was started more promptly in the group treated with erythromycin. In fact, when only those patients who began treatment within the first three days of illness are considered the total duration of the febrile period was significantly shorter in the group treated with tetracycline. Differences in the clinical point of view between patients on tetracycline and patients on erythromycin, however, were less apparent (delay of apyrexia of about 1 5 days), except in one case of unsuccessful treatment with erythromycin.
In conclusion, erythromycin could constitute an acceptable therapeutic alternative to tetracycline for children aged under 8 years with Mediterranean spotted fever, except those with severe symptoms or serious illness.
We acknowledge the help of Dr Marta Pulido for the English translation and copy editing of the manuscript. 
